Skip to main content

Table 3 Association of baseline sGFAP and sNfL with disease duration and time since last attack

From: Serum GFAP and NfL as disease severity and prognostic biomarkers in patients with aquaporin-4 antibody-positive neuromyelitis optica spectrum disorder

sGFAP sNfL
Time between baseline visit and Patient group (n) ηρ2 for interaction, p Std. effect size β (95% CI) p ηρ2 for interaction, p Std. effect size β (95% CI) p
First manifestation of diseasea AQP4-IgG+ (33) 0.05, p = 0.14 0.18 0.20 (− 0.84–1.24) 0.70 0.02, p = 0.40 − 1.27 − 1.37 (− 2.92–0.19) 0.08
MOG-IgG+ (16) − 0.96 − 1.10 (− 2.58–0.38) 0.14 − 1.99 − 2.14 (− 3.68 to − 0.60) 0.008
Last attacka AQP4-IgG+ (33) 0.03, p = 0.25 0.41 0.46 (− 0.55–1.47) 0.37 < 0.01, p = 0.80 − 1.22 − 1.32 (− 2.88–0.25) 0.10
MOG-IgG+ (16) -0.47 − 0.53 (− 1.96–0.91) 0.46 − 0.99 − 1.08 (− 2.63–0.48) 0.17
  1. aLinear models using log-transformed sGFAP and sNfL and time interval values, adjusted for age. Furthermore, an interaction term of baseline sGFAP or sNFL (log-transformed) and group was included to assess the statistical significance of inter group differences
  2. AQP4-IgG aquaporin-4 immunoglobulin G, β regression coefficient, CI confidence interval, ηρ2 partial eta-squared, MOG-IgG myelin oligodendrocyte protein immunoglobulin G, n number, NMOSD neuromyelitis optica spectrum disorders, sGFAP serum glial fibrillary acidic protein, sNfL serum neurofilament light chain protein, std. effect size standardized effect size